207 results about "Healthy control" patented technology

The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.

A method and system for monitoring tool performance for processing tools in a semiconductor processing system. The semiconductor processing system includes a number of processing tools, a number of processing modules, a number of sensors, and an alarm management system. A tool health control strategy is executed in which tool health data for the processing tool is collected. A tool health analysis strategy is executed in which the tool health data is analyzed. An intervention manager can pause the processing tool when an alarm has occurred. The intervention manager refrains from pausing the processing tool when an alarm has not occurred.

A two-dimensional (2D) chemical shift correlated MR spectroscopic (COSY) sequence integrated into a new volume localization technique (90°-180°-90°) for whole body MR Spectroscopy. Using the product operator formalism, a theoretical calculation of the volume localization as well as the coherence transfer efficiencies in 2D MRS is presented. A combination of different MRI transmit/receive rf coils is used. The cross peak intensities excited by the proposed 2D sequence are asymmetric with respect to the diagonal peaks. Localized COSY spectra of cerebral frontal and occipital gray/white matter regions in fifteen healthy controls are presented.

The application of the invention discloses an intelligent air conditioning system. The intelligent air conditioning system comprises a human body health state monitoring device, an indoor environmental monitoring device, a health controlling device and an air conditioner controller; the input end of the air conditioner controller is connected with the human body health state monitoring device and the indoor environmental monitoring device, and the output end of the air conditioner controller is connected with the health controller; the air conditioner controller is used for acquiring human body health indicator information and indoor environmental information in real time, finding information data which cannot meet requirements by judging and analyzing all information data, and controlling actuators corresponding to the information data which cannot meet the requirements to perform corresponding adjusting operations. As can be seen, the intelligent air conditioning system can adjust a condition by combining indoor environment and a human body health state; compared with the prior art that only indoor environment is taken into consideration during adjusting, the intelligence level of an intelligent air conditioner is improved greatly, so that the real intelligent health experience is brought to a user.

The present invention is related to methods of early diagnosis of ovarian cancer in a patient by determining serum levels of blood markers using a novel LabMAP™ technology (Luminex Corp., Austin, Tex.), which allows for simultaneous measurement of the blood markers in serum. The panel of blood markers offers extremely high predictive power for discrimination of ovarian cancer from both healthy control patients and from patients with benign pelvic/ovarian tumors. The methods of the present invention allow for rapid, early diagnosis of ovarian cancer with extremely high sensitivity and specificity to be clinically useful in disease diagnosis.

A vital signs detection system has a terminal capable of being connected to detecting means of detecting vital signs; a program server of storing a program and/or data to operate the detecting means; and an information server of communicating with the terminal; wherein: when an operation switch of the detecting means is turned ON, the terminal transmits information including the type of the detecting means to the program server; on receiving the information, the program server transmits a predetermined program and/or data corresponding to the information to the terminal according to the information; the detecting means operates according to the predetermined program and/or data received by the terminal, and thereby detects vital signs; and the terminal transmits the vital signs detected by the detecting means to the information server.

A method of health care financing, comprising: calculating an economic burden on an entity caused by a health situation; providing, by a third party, application and monitoring of a health plan for at least 10,000 individuals in least part of the entity; and paying to the third party in response to a proof that said burden is reduced.

The invention is suitable for the technical field of health control and provides a psychological pressure assessment method and apparatus. The method comprises the steps of collecting sample data, and constructing a feature data matrix, wherein the sample data specifically comprises physiological feature data, psychological feature data such as stress scale and the like, basic information of an individual and the like; performing preliminary assessment on the physiological feature data and the psychological feature data by a fuzzy C-mean algorithm and an ordered weighted arithmetic mean operator to obtain respective classification identification results; performing secondary classification whether the results are benign or not for the classification identification results in which psychological pressure exists according to a decision layer fusion model, and outputting secondary classification results in which the psychological pressure exists; and taking the secondary classification results as statistical model inputs, and obtaining a quantized value of the psychological pressure of the individual according to a pressure system theory model-based Cylinder pressure quantization function. According to the method and the apparatus, graded quantitative assessment of the psychological pressure is realized.

The invention relates to a microRNA standardization reference gene and an application thereof. Specifically, with Solexa sequencing, real-time fluorescence quantitative PCR detection, literature screening, statistical analysis methods, the invention carries out researches upon a large amount of samples collected from a healthy control group and different disease patients. As a result, microRNAs let-7d, let-7g, let-7i, or combinations thereof can serve as microRNA standardization housekeeping gene. Compared with reference genes (such as U6, RNU44, RNU48 and miR-16, and the like) most commonly used in current microRNA quantification, the microRNA standardization reference gene has high stability and accuracy.

This document relates to methods and materials involved in diagnosing SLE. For example, this document relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, this document provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls. In addition, methods and materials for assessing SLE activity, determining the likelihood of experiencing active SLE, and detecting SLE treatment effectiveness are provided herein.

The invention mainly aims at humanbody health assessment and personalized diagnosis of microbial flora relateddiseases, and proposes and validates an assessment and diagnosis method based on human body flora interaction network analysis. The method aims to detect the number of 15 kinds of special function nodes-containing triangle motifs (trios) in a flora interaction network, wherein there are two major categories including a branch with no special function nodes and a branch with function nodes, the branch with no special function nodes is divided in six typesaccording to positive and negative relations between three nodes, and the branch with the function nodes is divided in nine typesaccording to the number of interaction and positive and negative relations of the function nodes and the triangle motifs. The inventor finds that there is significant difference in the number of specific trios in the flora interaction network between experimental group/disease group and healthy controls by analyzing microbial flora data of six human body parts includingintestines, vaginas, lungs, mouths, semenand skin. The method provides an effective reference index forrisk assessment of humanbodyhealth and disease occurrence, and provides reliable technical support for the personalized diagnosis of the microbial flora relateddiseases.

The invention discloses an aeronautic health control system, which comprises a master control board, a digital board, an analogue board, a vibration board, a cache recording card and a protective recorder, wherein the master control board is connected with the digital board, the analogue board and the vibration board through a peripheral component interconnect (PCI) bus, is connected with the cache recording card through a serial advanced technology attachment (SATA) bus, and is connected with the protective recorder through an Ethernet bus. According to the system, a plurality of signals can be acquired, and the master control board is used for storing acquired data into the integrated cache recording card, so that acquisition and recording functions are realized by one piece of equipment; and maintenance data, status data and flight parameter data are synchronously acquired on an acquirer, and functions of data synchronization and important data filtration, forwarding and distribution to a flight parameter recorder for storage during ground playback analysis are realized in a time scale information packing and addition way. The aeronautic health control system can be widely applied to an automatic control system.

The invention provides a method for analyzing urine exosome miRNA, comprising: collecting a urine sample, extracting exosomes and their total RNA, establishing a cDNA library, performing Illumina sequencing, and processing and annotating the sequencing results to obtain expression information of sample miRNA expression quantity; urine sample exosome miRNA is analyzed by high-throughput sequencing technology to acquire expression information of miRNA; a database for IgA nephrotic patient and a healthy control patient is established, differentially expressed miRNA is deeply studied through target gene function prediction, the deep study on the differentially expressed miRNA helps further illustrate the pathogenesis of IgA nephropathy, and novel method and theoretical basis is provided for the diagnosis of IgA nephropathy. The method is reasonable and feasible in design, a noninvasive precise differential expression miRNA method can be effectively established, and novel ideas are provided for clinical diagnosis and treatment.

New markers for diseased liver conditions have been identified. A combination of protein C (PROC) and retinol binding protein 4 (RBP4) in blood are biomarkers to distinguish patients at different stages of hepatic fibrosis due, for example, to chronic infection with hepatitis C virus (HCV). Also, alpha-1-B glycoprotein (A1BG), complement factor H (CFH) and insulin-like growth factor binding protein acid labile subunit (IGFALS) distinguish subjects with chronic or acute liver conditions such as hepatitis infection or liver fibrosis from healthy controls.

A trash container includes a container unit and a sanitary and health control arrangement. The container unit includes a container having a top opening and a container cavity, and a container cover being moved between an opened position and a closed position. The sanitary and health control arrangement includes a monitoring module coupled at the container unit for collecting different trash information thereof, and a sanitary module operatively linked to the monitoring module for maintaining the container unit in a sanitary manner in response to the trash information.

The invention belongs to the field of genetic engineering and clinical medicine. The invention aims to provide peripheral white blood cell miRNA markers associated with the onset of human preeclampsia. The invention also aims to provide an application of the miRNA markers. The miRNA markers can be many of has-miR-15a-3p, has-miR-31-3p, has-miR-451a and has-miR-122-5p. The peripheral white blood cell miRNA markers include has-miR-15a-3p, has-miR-31-3p, has-miR-451a and has-miR-122-5p. The peripheral white blood cell miRNA marker is applied to preparation of reagent for diagnosis or monitoring of human preeclampsia. The reagent is capable of determining the expression of the peripheral white blood cell microRNA marker in peripheral white blood cell. According to the invention, verifications are carried out on samples in line with preeclampsia and samples of a healthy control population to prove that the expressions of the markers are significantly different and the markers have stability and thus the results demonstrate that the markers have specificity and can be used as markers.

UL16 binding protein 2 (ULBP2) is a protein overexpressed in pancreatic cancer tissues, and the ULBP2 levels are significantly higher in pancreatic cancer patients than those in healthy controls. This invention provides a method to detect pancreatic cancer using ULBP2 as a serological marker. The combination of ULBP2 and CA19-9 promotes the efficacy of pancreatic cancer detection. When measuring the blood ULBP2 levels in patients with other cancer types, including colorectal carcinoma, nasopharyngeal carcinoma and gastric cancer illustrates the blood ULBP2 levels are higher in patients with pancreatic cancer than other cancer types.

The invention relates to a method for cancer diagnosis and/or cancer risk hazard degree assessment in subjects. The method comprises the following steps: a) determining DNA methylation states of samples from the subjects and samples from a healthy control group on at least one DNA methylation site; b) comparing the DNA methylation states of the samples from the subjects at the DNA methylation site with the DNA methylation states of the samples from the healthy control group at the corresponding DNA methylation site; and if the methylation states of the samples from the subjects and the samples from the healthy control group have remarkable difference, showing that the subjects have cancers or have cancer risks. The invention further provides a kit for the method provided by the invention.

The invention relates to a method for recognizing a spatial difference by utilizing a complex number fMRI (functional magnetic resonance imaging) space source phase, belonging to the technical field of biomedical signal processing. The method comprises the following steps of carrying out spatial ICA (independent component analysis) separation on complex number fMRI data, choosing an interesting ingredient, then performing phase correction and noise elimination to obtain the spatial source phase of the interesting ingredient, and finally, calculating through a variance homogeneity analysis anda variance difference coefficient so as to recognize the differences of SZs and HCs in the spatial source phase. Compared with widely applied amplitude data, the method utilizes the spatial source phase to recognize the spatial difference between a schizophrenia patient group and a healthy control group, and can display higher flexibility and reliability. For example, specific to complex number fMRI data of 82 testees in a quiescent condition, the spatial source phase is used for extracting differential voxel, which is increased by more than 122.95% in DMN, on the premise of not using FDR correction, and the differential voxel, which is extracted from the spatial source phase and can pass the FDR correction, is 69% more than the amplitude.

The invention relates to a diagnosis kit for Parkinson's disease, and application of the diagnosis kit. According to the diagnosis kit, single-blind detection is carried out on the expression levels of miR-105-5p, miR-21-5p, miR-29a-5p and miR-30e-5p in plasma of 263 patients with the Parkinson's disease and a healthy control group of 242 hpersons having matched ages and sexes, and the four miRNAs are found to be significantly different in the plasma of patients with the Parkinson's disease and the plasma of healthy people, so that the four miRNAs are suggested to used as a molecular marker for preparing the kit for the Parkinson's disease, or to be used for preparing medicines for treating the Parkinson's disease. After the kit is used, the medication compliance has remarkable influence on the miR-21-5p, so that the kit can be used for screening the medicines for treating the Parkinson's disease.

Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from healthy controls. Such comparison characterizes the test subject's risk of developing CVD.

The invention discloses a preparation method for serum miRNAs specific to active pulmonary tuberculosis. The method comprises the following steps: A1, collection and clinical detection of serum samples of patients with active pulmonary tuberculosis and healthy controls; A2, extraction of total RNAs from the serum samples; A3, high flux sequencing and screening of serum miRNAs specific to active pulmonary tuberculosis; and A4, designing of stem-loop reverse transcription primers, upstream primers and downstream primers of miRNAs, wherein the stem-loop reverse transcription primers are SEQ ID No. 10 to SEQ ID No. 18, a commonly-used upstream primer is SEQ ID No. 19 and a commonly-used downstream primer is SEQ ID No. 28. According to the invention, to prepare serum miRNAs specific to active pulmonary tuberculosis, high flux sequencing is used for preliminary screening of differentially expressed serum miRNAs, specific reverse transcription primers are designed by using a stem-loop method, and verification is carried out by using a fluorescence quantitative method so as to obtain the differentially expressed serum miRNAs; the serum miRNAs have remarkable significance to research on control of propagation of pulmonary tuberculosis and to reduction of the incidence rate of pulmonary tuberculosis.